RxDoctor Payments Data

Shannon Ferguson, PA

Physician Assistant · Fort Worth, TXNPI 1407294259

Payments from drug & device makers

$8,530in general payments, 2019–2025

Across 431 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • Pfizer$944
  • AbbVie$660
  • Novo Nordisk$626
  • Boehringer Ingelheim$599
  • AstraZeneca$549
  • plus $4K from 42 others

What the payments were for

  • Consulting fees$8009%
  • Travel & lodging$3414%
  • Food & beverage$7,29986%
  • Education$901%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,530 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$47,894
Medicare patients
145
Services billed
1,015

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$108,375
TrulicityDulaglutide34$36,054
JardianceEmpagliflozin41$35,584
EliquisApixaban26$29,497
MounjaroTirzepatide11$19,187
RybelsusSemaglutide16$15,399
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$15,234
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$11,000
Synjardy XrEmpagliflozin/Metformin Hcl13$10,256
Celecoxib51$3,023
Pregabalin35$2,564
Duloxetine Hcl74$2,072
Rosuvastatin Calcium154$1,987
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,436
Atorvastatin Calcium154$1,319

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$626$123,77490 claims
Lilly USA, LLCTrulicity, Mounjaro$416$55,24145 claims
Boehringer IngelheimJardiance, Synjardy Xr$599$45,84054 claims
PfizerEliquis$944$29,49726 claims
GSKTrelegy Ellipta$190$15,23416 claims
AstraZenecaBreztri Aerosphere$549$11,00017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Fort Worth

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →